<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04676958</url>
  </required_header>
  <id_info>
    <org_study_id>200190189</org_study_id>
    <nct_id>NCT04676958</nct_id>
  </id_info>
  <brief_title>viTAmin K2 and rEcOVery From ExeRcise</brief_title>
  <acronym>TAKEOVER</acronym>
  <official_title>Effects of Vitamin K2 on Recovery From Muscle Damaging Exercise in Young and Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kappa Bioscience</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Glasgow</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study, therefore, is to investigate the effects of vitamin K2&#xD;
      supplementation on the physiological responses to an acute bout of resistance exercise.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in post exercise recovery of muscle strength</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Muscle strength (MVC) of the knee extensor muscles will be measured before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pain free range of motion during knee extension exercise</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>The range of motion which is pain free will be measured during knee extension using a goniometer before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in post exercise recovery of functional abilities</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Time to complete 5 chair rises will be measured before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in post exercise recovery of sEMG activity</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Quadriceps muscle sEMG will be measured before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in post exercise interleukin-6</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Circulating interleukin-6 will be measured before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in post exercise peroxiredoxin 3 redox state</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Circulating peroxiredoxin 3 redox state will be measured before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vitamin K levels</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Vitamin K will be measured in baseline and 12 week samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Carboxylated Osteocalcin levels</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Carboxylated Osteocalcin will be measured in baseline and 12 week samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in uncarboxylated Osteocalcin levels</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>uncarboxylated Osteocalcin will be measured in baseline and 12 week samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in carboxylated matrix gla-protein levels</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>carboxylated matrix gla-protein will be measured in baseline and 12 week samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dephosphorylated-uncarboxylated matrix gla-protein levels</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>dephosphorylated-uncarboxylated matrix gla-protein will be measured in baseline and 12 week samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in post exercise F2 isoprostanes</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Circulating F2 isoprostanes will be measured before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in lean mass</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Change in lean mass</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in blood glucose</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Change in blood glucose</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in blood lipids</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Change in blood lipids</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in plasma insulin</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Change in plasma insulin</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in fat mass</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Change in fat mass</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in muscle thickness</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Change in muscle thickness</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in exercise substrate utilisation</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Energy expenditure, carbodhydrate and fat oxidation during treadmill walking</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Inflammation</condition>
  <condition>Oxidative Stress</condition>
  <condition>Vitamin K</condition>
  <condition>Exercise</condition>
  <condition>Strength</condition>
  <condition>Recovery</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>380 mg capsule/day micro-crystalline cellulose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin K2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>380 mg capsule/day micro-crystalline cellulose including 240ug/day Vitamin K2</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin K2</intervention_name>
    <description>Vitamin K2</description>
    <arm_group_label>Vitamin K2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Micro-crystalline cellulose</intervention_name>
    <description>Micro-crystalline cellulose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is able and willing to sign the Informed Consent From&#xD;
&#xD;
          -  No plans to change lifestyle (activity and nutrition) during the study period&#xD;
&#xD;
          -  Older group (n=40): 65 years of age or older.&#xD;
&#xD;
          -  Younger group (n=40): Aged 18-40 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not currently, or in the last year, participating in more than 1h per week of vigorous&#xD;
             aerobic physical activity or any resistance exercise&#xD;
&#xD;
          -  BMI &gt; 30 kg/m2&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  severe cardiovascular disease&#xD;
&#xD;
          -  seizure disorders&#xD;
&#xD;
          -  liver disease&#xD;
&#xD;
          -  uncontrolled hypertension (&gt;150/90mmHg at baseline measurement)&#xD;
&#xD;
          -  cancer or cancer that has been in remission &lt;5 years&#xD;
&#xD;
          -  ambulatory impairments which would limit ability to perform assessments of muscle&#xD;
             function&#xD;
&#xD;
          -  dementia&#xD;
&#xD;
          -  currently taking Vitamin K2 supplements&#xD;
&#xD;
          -  currently taking Vitamin K antagonists/anticoagulants (e.g. warfarin)&#xD;
&#xD;
          -  current smoking&#xD;
&#xD;
          -  history of drug abuse&#xD;
&#xD;
          -  taking medication known to affect muscle (e.g. steroids).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Glasgow</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 8TA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr H Lithgow, PhD</last_name>
      <phone>0141 330 2569</phone>
      <email>hannah.lithgow@glasgow.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stuart Robert Gray</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart R Gray</last_name>
      <phone>01413302569</phone>
      <email>stuart.gray@glasgow.ac.uk</email>
    </contact>
    <contact_backup>
      <phone>01413302569</phone>
      <phone_ext>Gray</phone_ext>
      <email>stuart.gray@glasgow.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Stuart R Gray, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Glasgow</investigator_affiliation>
    <investigator_full_name>Stuart Gray</investigator_full_name>
    <investigator_title>Senior Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

